Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRBS.L Regulatory News (RBS)

  • There is currently no data for RBS

Trading Update

30 Sep 2014 07:00

RNS Number : 9598S
Royal Bank of Scotland Group PLC
30 September 2014
 



The Royal Bank of Scotland Group plc ("RBS")

 

Q3 2014 Trading Update and Presentation at Bank of America Merrill Lynch Banking & Insurance Conference

 

30 September 2014

 

Presentation at Bank of America Merrill Lynch Banking & Insurance Conference

 

Ross McEwan, RBS Chief Executive, will present at the Bank of America Merrill Lynch Banking & Insurance Conference in London on Tuesday 30 September 2014 at 9.30am (UK time). 

 

A live audio webcast and accompanying slides will be available on our website www.rbs.com/ir shortly before the presentation commences.

 

Q3 2014 Trading Update

 

RBS today provides an update on Q3 2014 financial performance.

 

· Q3 2014 has seen continued improvement in economic conditions and asset prices in our key markets, including Ireland. This has supported a further quarter of strong operating performance by RBS Capital Resolution ("RCR"). We anticipate that RCR will record net impairment provision releases in the region of £0.5bn in Q3 2014.

 

· RCR's future overall costs and speed of wind-down remain subject to significant potential volatility. The potential exists, if market conditions remain favourable, for RCR to incur limited future impairments and disposal losses, and an accelerated timetable to achieve its wind-down goals.

 

· Rising Irish residential property prices combined with pro-active debt management has resulted in lower arrears in Ulster (excluding RCR), within Personal & Business Banking. As a result we expect Ulster to record net provision releases in the region of £0.3bn in Q3 2014. The potential exists for further releases in future, if market conditions continue to improve.

 

· There has been an absence of large one-off impairments and lower levels of new non-performing loans in the rest of RBS's business during Q3 2014.

 

· RBS now expects to significantly outperform its previous guidance of c£1bn total impairments for FY 2014. Previously disclosed uncertainties remain, particularly relating to conduct and litigation matters.

 

· Corporate & Institutional Banking revenues have been weaker than anticipated in the third quarter.

 

· RBS took advantage of improved market prices to dispose of c€9bn legacy available for sale debt securities. These disposals generated a loss of around £0.2bn in Centre revenues. We expect these transactions to be moderately capital ratio accretive.

 

The figures quoted in this statement are preliminary estimates and unaudited. RBS will release its Q3 2014 Interim Management Statement on 31 October 2014.

 

 

For further information:

 

Investor Relations

Richard O'Connor

Head of Investor Relations

+44 (0) 20 7672 1758

 

Media Relations

+44 (0) 131 523 4205

 

If you would like a copy of this presentation in a different format (eg. large print, audio or Braille) please contact the Investor Relations team on +44 20 7672 1758 or investor.relations@rbs.com.

 

This release contains 'forward-looking statements' as that term is defined in the United States Private Securities Litigation Reform Act of 1995. Forward looking statements are statements that are not historical facts and can be identified by the use of forward-looking terminology such as statements that include the words 'expect', 'estimate', 'project', 'anticipate', 'believes', 'should', 'intend', 'plan', 'could', 'probability', 'risk', 'Value-at-Risk (VaR)', 'target', 'goal', 'objective', 'will', 'endeavour', 'outlook', 'optimistic', 'prospects' and similar expressions or variations on such expressions or by the forward looking nature of discussions of strategy, plans, targets and intentions. . These statements are based on current plans, estimates and projections, and are subject to inherent risks, uncertainties and other factors which could cause actual results to differ materially from the future results expressed or implied by such forward-looking statements. The forward-looking statements contained in this release speak only as of the date of this announcement, and the Group does not undertake to update any forward-looking statement to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. The information, statements and opinions contained in this document do not constitute a public offer under any applicable legislation or an offer to sell or solicitation of any offer to buy any securities or financial instruments or any advice or recommendation with respect to such securities or other financial instruments.

 

ENDS

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQKKDPPBKKKCN
Date   Source Headline
17th Mar 20205:24 pmRNSDirectorate Change
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:38 pmRNSPrice Monitoring Extension
17th Mar 20208:30 amRNSMorgan Stanley European Financials Conference
16th Mar 20205:14 pmRNSNatWest Markets N.V. 2019 ARA
10th Mar 20204:51 pmRNSDirector/PDMR Shareholding
2nd Mar 20202:34 pmRNSDirector/PDMR Shareholding
28th Feb 20204:29 pmRNSCorrection of Dividend Declaration
28th Feb 20201:58 pmRNSTotal Voting Rights and Capital
28th Feb 20207:00 amRNSFiling of Annual Report on Form 20-F with US SEC
27th Feb 20209:55 amRNSBlock Listing Cancellation
24th Feb 202012:40 pmRNSDividend Declaration
20th Feb 20204:10 pmRNSHolding(s) in Company
14th Feb 20203:58 pmRNSRBSG ENTM Publication of Suppl.Prospcts
14th Feb 20207:01 amRNSAnnual Financial Report
14th Feb 20207:00 amRNSFinal Results
31st Jan 20202:12 pmRNSTotal Voting Rights and Capital
30th Jan 20203:57 pmRNSDirector/PDMR Shareholding
16th Jan 20202:08 pmRNSForm 8.3 - Accesso Technology Group plc
2nd Jan 20201:58 pmRNSForm 8.3 - Accesso Technology Group plc
31st Dec 20191:10 pmRNSDirector/PDMR Shareholding
31st Dec 201911:20 amRNSTotal Voting Rights and Capital
30th Dec 20193:02 pmRNSForm 8.3 - Accesso Technology Group plc
20th Dec 20197:00 amRNSPublication of Suppl.Prospcts replacement
19th Dec 20195:40 pmRNSPublication of Suppl.Prospcts
19th Dec 20197:00 amRNSNatWest Markets Change in Executive Directors
16th Dec 20195:47 pmRNS2019 Bank of England stress test results
4th Dec 201912:34 pmRNSForm 8.3 - Accesso Technology Group plc
2nd Dec 20195:34 pmRNSPublication of Suppl.Prospcts
29th Nov 20192:20 pmRNSDirector/PDMR Shareholding
29th Nov 20191:28 pmRNSAnnouncement of NatWest Markets N.V. Transfer
29th Nov 201912:01 pmRNSTotal Voting Rights and Capital
27th Nov 201911:56 amRNSDividend Declaration
21st Nov 20196:26 pmRNSPublication of a Prospectus
21st Nov 201910:45 amRNSReduction in Pillar 2A capital requirements
14th Nov 201911:23 amRNSPublication of Final Terms
13th Nov 20193:00 pmRNSForm 8.3 - Accesso Technology Group plc
8th Nov 20193:00 pmRNSDirector/PDMR Shareholding
1st Nov 20194:12 pmRNSDirector/PDMR Shareholding
31st Oct 20193:30 pmRNSDirector/PDMR Shareholding
31st Oct 20192:08 pmRNSTotal Voting Rights and Capital
30th Oct 20199:38 amRNSRBSG pricing of US$750mn of Subordinated Notes
25th Oct 20195:22 pmRNSPublication of Suppl.Prospcts
24th Oct 20197:00 amRNSQ3 Interim Management Statement
16th Oct 20192:54 pmRNSForm 8.3 - Accesso Technology Group plc
8th Oct 201911:35 amRNSBlock Listing Six Monthly Return
3rd Oct 20191:08 pmRNSPublication of Final Terms
1st Oct 20195:29 pmRNSDirector/PDMR Shareholding
30th Sep 20193:28 pmRNSTotal Voting Rights
24th Sep 20198:30 amRNSBank of America Merrill Lynch Annual Conference

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.